A meta analysis of subtype-specific prognostic significance of METTL3 expression in non-small cell lung cancer

A meta analysis of subtype-specific prognostic significance of METTL3 expression in non-small cell lung cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article A meta analysis of subtype-specific prognostic significance of METTL3 expression in non-small cell lung cancer Liu Zichang, Ren Jiachen, Zhang Yaning, Gan Zhengyang, Wei Liu, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7301948/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objective: This study aimed to systematically synthesize evidence regarding the association between METTL3 expression and clinical outcomes in patients with non-small-cell lung cancer (NSCLC). Methods: A comprehensive literature search was conducted across CNKI, PubMed, Embase, Web of Science, and ScienceDirect, encompassing all relevant studies published from database inception to January 1, 2024. Study quality was evaluated using the Newcastle–Ottawa Scale (NOS). Meta-analyses were performed using RevMan 5.3 and Stata 18.0, with hazard ratios (HRs) and 95% confidence intervals (CIs) as the primary effect measures. Results: Nine eligible cohort studies involving 2,754 patients were included. Pooled analyses revealed that high METTL3 expression was significantly associated with poorer overall survival (OS) in lung adenocarcinoma (LUAD) (HR = 0.79, 95% CI: 0.67–0.94; P = 0.006). In contrast, no statistically significant association was observed in lung squamous-cell carcinoma (LUSC) (HR = 0.99, 95% CI: 0.91–1.07; P = 0.81). Further subgroup analysis restricted to studies with a follow-up period exceeding 10 months demonstrated a pronounced prognostic effect of METTL3 in the overall NSCLC cohort (HR = 0.20, 95% CI: 0.04–0.85; P = 0.03). Conclusion: Aberrant METTL3 expression may serve as a potential prognostic biomarker specifically in LUAD, with its prognostic value becoming more prominent after 10 months of follow-up. Non-small-cell lung cancer METTL3 m6A Prognosis Meta-analysis Full Text Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7301948","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":509992510,"identity":"5913c5af-0201-481b-9949-1e6fa6d4c4ae","order_by":0,"name":"Liu Zichang","email":"","orcid":"","institution":"Beijing Anzhen Hospital","correspondingAuthor":false,"prefix":"","firstName":"Liu","middleName":"","lastName":"Zichang","suffix":""},{"id":509992511,"identity":"4a69d3e9-c374-4d3d-ad7c-ae6ab4fecc01","order_by":1,"name":"Ren Jiachen","email":"","orcid":"","institution":"Beijing Anzhen Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ren","middleName":"","lastName":"Jiachen","suffix":""},{"id":509992512,"identity":"74fd91fd-cd69-4b01-b8cf-9d14f70a2196","order_by":2,"name":"Zhang Yaning","email":"","orcid":"","institution":"Beijing Anzhen Hospital","correspondingAuthor":false,"prefix":"","firstName":"Zhang","middleName":"","lastName":"Yaning","suffix":""},{"id":509992513,"identity":"3107d175-ff13-4735-90d3-138b41ab3df4","order_by":3,"name":"Gan Zhengyang","email":"","orcid":"","institution":"Beijing Anzhen Hospital","correspondingAuthor":false,"prefix":"","firstName":"Gan","middleName":"","lastName":"Zhengyang","suffix":""},{"id":509992514,"identity":"76225393-ee97-4bb1-bd73-3adb9bb2e5ac","order_by":4,"name":"Wei Liu","email":"","orcid":"","institution":"Hebei Medical University","correspondingAuthor":false,"prefix":"","firstName":"Wei","middleName":"","lastName":"Liu","suffix":""},{"id":509992515,"identity":"7065e490-52dc-46f4-89e2-cc98bea86374","order_by":5,"name":"Wu Yanjing","email":"","orcid":"","institution":"Beijing Anzhen Hospital","correspondingAuthor":false,"prefix":"","firstName":"Wu","middleName":"","lastName":"Yanjing","suffix":""},{"id":509992516,"identity":"b91fbede-c2dd-4bfb-92b0-f58ece431d07","order_by":6,"name":"Wang Xifu","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAu0lEQVRIiWNgGAWjYFACxgcHJH7YyLGxtx8gVguz4QPLnjRjPp4zCURrMTaoYDucOE/CwYA4DQY3ktkkbvAcTm+TYEhg+FGxjQgtZw6zSc6wSM9tk248wNhz5jZhLWbH+49JS/BY57bJHEhgZmwjRsthZjbpP2zM6WwSCQZEajnezGwgweacQLwW+zOHGR9I9qQZtgED+SBRfpGckcwAikp5+fb2gw9+VBChBQUcIFH9KBgFo2AUjAJcAADMdjrRCOw+0QAAAABJRU5ErkJggg==","orcid":"","institution":"Beijing Anzhen Hospital","correspondingAuthor":true,"prefix":"","firstName":"Wang","middleName":"","lastName":"Xifu","suffix":""}],"badges":[],"createdAt":"2025-08-05 14:53:24","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7301948/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7301948/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":94648635,"identity":"ebd917e7-39ce-45d5-b8b6-a67b9c31e78c","added_by":"auto","created_at":"2025-10-29 09:09:57","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":941056,"visible":true,"origin":"","legend":"","description":"","filename":"AmetaanalysisofsubtypespecificprognosticsignificanceofMETTL3expressioninnonsmallcelllungcancer.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7301948/v1_covered_bbc8f197-9268-4fb3-a8e1-0afa0746abc1.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"A meta analysis of subtype-specific prognostic significance of METTL3 expression in non-small cell lung cancer","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Non-small-cell lung cancer, METTL3, m6A, Prognosis, Meta-analysis","lastPublishedDoi":"10.21203/rs.3.rs-7301948/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7301948/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eObjective: This study aimed to systematically synthesize evidence regarding the association between METTL3 expression and clinical outcomes in patients with non-small-cell lung cancer (NSCLC).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eMethods: A comprehensive literature search was conducted across CNKI, PubMed, Embase, Web of Science, and ScienceDirect, encompassing all relevant studies published from database inception to January 1, 2024. Study quality was evaluated using the Newcastle–Ottawa Scale (NOS). Meta-analyses were performed using RevMan 5.3 and Stata 18.0, with hazard ratios (HRs) and 95% confidence intervals (CIs) as the primary effect measures.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eResults: Nine eligible cohort studies involving 2,754 patients were included. Pooled analyses revealed that high METTL3 expression was significantly associated with poorer overall survival (OS) in lung adenocarcinoma (LUAD) (HR = 0.79, 95% CI: 0.67–0.94; P = 0.006). In contrast, no statistically significant association was observed in lung squamous-cell carcinoma (LUSC) (HR = 0.99, 95% CI: 0.91–1.07; P = 0.81). Further subgroup analysis restricted to studies with a follow-up period exceeding 10 months demonstrated a pronounced prognostic effect of METTL3 in the overall NSCLC cohort (HR = 0.20, 95% CI: 0.04–0.85; P = 0.03).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eConclusion: Aberrant METTL3 expression may serve as a potential prognostic biomarker specifically in LUAD, with its prognostic value becoming more prominent after 10 months of follow-up.\u003c/p\u003e","manuscriptTitle":"A meta analysis of subtype-specific prognostic significance of METTL3 expression in non-small cell lung cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-09-05 21:57:04","doi":"10.21203/rs.3.rs-7301948/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"f264feee-f333-48d5-a7da-42aa52325bb8","owner":[],"postedDate":"September 5th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-10-29T09:09:27+00:00","versionOfRecord":[],"versionCreatedAt":"2025-09-05 21:57:04","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7301948","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7301948","identity":"rs-7301948","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}